Praluent Cost in Delaware 2026: Price, Insurance, Medicaid, and Compounding Options

What Is Alirocumab and Why Does It Cost So Much?

Alirocumab is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors in the liver. By blocking PCSK9, alirocumab keeps LDL receptors active longer, which pulls more LDL cholesterol out of the bloodstream. The FDA approved Praluent in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering on top of maximally tolerated statin therapy. [1]

Monoclonal antibodies are expensive to manufacture. The upstream biologic production process, cell culture, purification, and cold-chain storage all drive costs that small-molecule drugs do not carry. That is why alirocumab's wholesale acquisition cost lands near $580 per month in 2026, a price that has remained relatively stable since Regeneron and Sanofi cut it by roughly 60% in 2019 after payer resistance to earlier pricing. [2]

The clinical case for the drug is strong. ODYSSEY OUTCOMES enrolled 18,924 patients with recent acute coronary syndrome and randomized them to alirocumab 75 mg to 150 mg every two weeks versus placebo on top of high-intensity statin. At a median follow-up of 2.8 years, alirocumab reduced the primary composite endpoint (coronary heart disease death, nonfatal MI, ischemic stroke, or unstable angina requiring hospitalization) by 15% (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001). [3] Patients whose baseline LDL was at or above 100 mg/dL gained the most absolute benefit, with a number-needed-to-treat of 16 over 3 years in that subgroup. [3]

The ACC/AHA 2022 cholesterol guideline specifically recommends a PCSK9 inhibitor for very-high-risk ASCVD patients whose LDL remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe. [4] That recommendation is what most Delaware insurers and Medicaid use as the template for prior authorization criteria.

Praluent List Price vs. Real Out-of-Pocket Cost in Delaware

The $580 per month list price is almost never what a patient pays. Four distinct cost pathways exist for Delaware residents in 2026.

Pathway 1: Commercial insurance with a manufacturer savings card. Regeneron and Sanofi offer a copay assistance program. Commercially insured patients with an approved claim may pay as little as $0 per month, with Regeneron/Sanofi covering up to $3,600 per year in cost-sharing. Income limits do not apply; the restriction is that the patient must be commercially insured (Medicare and Medicaid enrollees are excluded by federal anti-kickback rules). Patients can enroll at the manufacturer's savings portal or ask their HealthRX prescriber to initiate enrollment at the time of the visit. [5]

Pathway 2: Delaware Medicaid (covered with PA). Delaware's Medicaid program, administered through managed care organizations including Highmark Delaware and Molina, covers alirocumab on the preferred drug list with prior authorization. The PA criteria generally require documentation of an LDL at or above 100 mg/dL on maximally tolerated statin therapy, a diagnosis of HeFH or established ASCVD (prior MI, stroke, or peripheral artery disease), and failure or intolerance of at least one statin at the highest tolerated dose. [6] When the PA is approved, patient cost-sharing under Delaware Medicaid is minimal, often $3 or less per fill under standard Medicaid pharmacy benefits.

Pathway 3: Medicare Part D. Medicare does not allow manufacturer copay cards. Alirocumab is covered under most Delaware Part D plans, but formulary placement varies. Some plans place it on Tier 4 or 5, which means coinsurance of 25 to 33%. At $580 list, that can mean $145 to $190 per month before reaching the catastrophic coverage threshold. The Medicare Extra Help (Low Income Subsidy) program can reduce this to under $12 per fill for qualifying beneficiaries. Patients may apply through the Social Security Administration. [7]

Pathway 4: Cash pay or compounded alirocumab. Without insurance and without a savings card, the full $580 list price applies at Delaware retail pharmacies. No major generic entry exists for alirocumab as of mid-2025 because biologic patents have not fully expired. The practical alternative for uninsured or underinsured Delaware patients is compounded alirocumab from a licensed 503A compounding pharmacy (discussed in full below).

Does Delaware Medicaid Cover Praluent?

Delaware Medicaid covers alirocumab, but the prior authorization process matters. PA approval is not guaranteed, and the clinical documentation required is specific. Prescribers must submit chart notes confirming the ASCVD or HeFH diagnosis, a lipid panel drawn while on maximally tolerated statin (with dose and duration documented), and a note addressing why further LDL reduction is clinically necessary. [6]

The American College of Cardiology and American Heart Association published a joint scientific statement noting that "PCSK9 inhibitors reduce LDL-C by 50 to 60 percent on top of statin therapy and have demonstrated significant reductions in cardiovascular events in large randomized controlled trials," citing ODYSSEY OUTCOMES and FOURIER as the primary evidence base. [4] Citing this statement directly in the PA letter can strengthen the clinical justification.

Approval timelines for Delaware Medicaid PA requests average 5 to 10 business days under standard review. Urgent PA requests, available when a patient has had a hospitalization for ACS within the prior 90 days, may be processed within 72 hours. If the first PA is denied, Delaware law (Title 18, Chapter 33 of the Delaware Code) gives enrollees the right to a first-level internal appeal within 30 days and an external independent review if the internal appeal fails.

Initial PA approvals are typically granted for 12 months. Renewal requires a follow-up lipid panel showing LDL reduction of at least 30%, confirming the drug is working as intended.

Is Compounded Alirocumab Legal in Delaware?

Compounded alirocumab is legal in Delaware through a state-licensed 503A compounding pharmacy. Delaware follows the federal framework established by the Drug Quality and Security Act of 2013, which allows 503A pharmacies to compound drugs based on a patient-specific prescription from a licensed prescriber. [8] Alirocumab is not on the FDA's current 503A Bulks List, but compounding pharmacies may use API (active pharmaceutical ingredient) sourced from an FDA-registered supplier to produce patient-specific formulations.

The legal and regulatory distinction matters. A 503A pharmacy compounds for individual patients only. It cannot produce large batches for general sale. The compounded product is not FDA-approved, which means potency, sterility, and bioavailability are not independently verified in the same way as the branded product. HealthRX physicians require patients using compounded alirocumab to obtain a baseline and 8-week follow-up lipid panel to confirm the expected LDL reduction of 40 to 60% is occurring. [9]

Cash price for compounded alirocumab through a 503A pharmacy in Delaware may be substantially lower than the $580 brand list price, and in some cases is covered as a pharmacy benefit by certain self-funded employer plans. Patients interested in this option should discuss it directly with their HealthRX prescriber, who can match the appropriate dose (75 mg or 150 mg per injection) and injection schedule to the commercial product's dosing regimen.

The HealthRX Alirocumab Access Framework for Delaware patients ranks cost pathways by expected out-of-pocket exposure:

1. Commercial insurance plus manufacturer savings card: target $0/month
2. Delaware Medicaid with approved PA: $0 to $3/month
3. Medicare Part D with Extra Help: under $12/month
4. Medicare Part D without Extra Help: $145 to $190/month (Tier 4 or 5)
5. Compounded alirocumab via 503A with self-funded employer plan: varies, often $30 to $80/month
6. Full cash pay (brand): approximately $580/month

Which Insurance Plans Cover Praluent in Delaware?

Most commercial plans sold on the Delaware Health Insurance Marketplace cover alirocumab, but formulary tier placement differs by carrier. Highmark Blue Cross Blue Shield Delaware, Aetna, Cigna, and UnitedHealthcare all include alirocumab on their 2026 formularies with a prior authorization requirement. [10] The key difference between plans is whether they place the drug on Tier 3 (preferred specialty, often 20 to 30% coinsurance) or Tier 4 (non-preferred specialty, often 40 to 50% coinsurance).

Before the savings card calculation, Tier 3 placement on a plan with a $4,000 deductible could mean the patient pays the full $580 per month until the deductible is met, then 20 to 30% afterward. The manufacturer savings card offsets up to $3,600 per year, which covers approximately six months at full list price or a full year of post-deductible coinsurance at 20 to 30%. Patients whose annual coinsurance exposure exceeds $3,600 should ask their prescriber about a formulary exception to move alirocumab to a lower tier, citing the ACC/AHA 2022 guideline recommendation and ODYSSEY OUTCOMES event-reduction data. [4]

Delaware employers with self-funded ERISA plans are not bound by state insurance mandates, but the majority of large Delaware employers (above 500 employees) cover PCSK9 inhibitors with PA as of 2026, reflecting updated clinical guidance and the cardiovascular mortality reduction data from ODYSSEY OUTCOMES. [3]

Can I Get Praluent via Telehealth in Delaware?

Prescribing alirocumab via telehealth is permitted in Delaware. Delaware law (24 Del. C. § 1769D) allows a licensed Delaware physician or advanced practice provider to establish a valid prescriber-patient relationship through synchronous audio-video telehealth and prescribe non-controlled medications, including biologic injectables like alirocumab, without an in-person visit. [11]

A HealthRX telehealth visit for alirocumab initiation includes a structured cardiovascular risk assessment, review of current statin regimen and tolerance, lipid panel review, and prior authorization initiation if the patient has commercial insurance or Delaware Medicaid. The visit typically takes 20 to 30 minutes. Prescriptions are sent electronically to a Delaware pharmacy of the patient's choice or to a mail-order pharmacy for home delivery.

Follow-up lipid panels are required at 4 to 8 weeks after the first injection to confirm LDL response. Most HealthRX patients use a local Delaware LabCorp or Quest Diagnostics location for the draw. Results are reviewed asynchronously by the prescribing clinician, who adjusts dose from 75 mg to 150 mg every two weeks if the LDL target has not been reached. [1]

How to Get the Lowest Praluent Price in Delaware: Step-by-Step

Getting the lowest possible price requires matching the right cost pathway to the patient's insurance status before the first prescription is written.

Step 1: Confirm your insurance status. Bring your insurance card to the telehealth visit. The prescriber's team will verify formulary coverage, PA requirements, and tier placement in real time.

Step 2: Apply for the manufacturer savings card. If you have commercial insurance, the HealthRX care coordinator can submit the Regeneron/Sanofi enrollment on your behalf during or immediately after the visit. Approval is typically instant for commercially insured patients.

Step 3: If you have Delaware Medicaid, prepare the PA documentation. Your prescriber will need your most recent lipid panel (drawn on current statin therapy), a medication history showing the statin name and dose, and your primary ASCVD or HeFH diagnosis code. Submitting complete documentation at the first PA attempt reduces denial rates significantly.

Step 4: If you are uninsured, ask about compounded alirocumab. A HealthRX prescriber licensed in Delaware can write a prescription for a 503A-compounded formulation. The prescriber will specify the dose, concentration, and injection schedule to match the FDA-approved product.

Step 5: Schedule your 8-week lipid panel. Alirocumab typically reduces LDL by 40 to 60% from baseline within 4 to 8 weeks. [9] Confirming the reduction serves as both a clinical checkpoint and documentation for PA renewal.

Alirocumab Dosing, Side Effects, and What to Expect

Alirocumab is supplied as a 1 mL prefilled pen or syringe. Starting dose is 75 mg subcutaneously every two weeks. If the 4- to 8-week LDL response is insufficient, the dose may be titrated to 150 mg every two weeks. An alternative monthly dosing regimen of 300 mg once monthly is available and approved, offering a dosing schedule some patients prefer for convenience. [1]

Injection site reactions (erythema, bruising, pain) occur in approximately 7% of patients in key trials versus 5% with placebo. [1] Nasopharyngitis and upper respiratory tract infection were the most common non-injection-site adverse events in ODYSSEY OUTCOMES, occurring at similar rates in the alirocumab and placebo arms. [3]

Neurocognitive effects received attention after early PCSK9 inhibitor trials reported anecdotal memory complaints. ODYSSEY OUTCOMES measured neurocognitive events prospectively and found no statistically significant difference between alirocumab and placebo (1.2% vs. 1.3%, respectively, P<0.05 for non-inferiority). [3] The FDA label includes a class-level note about neurocognitive events but does not identify a causal relationship. [1]

Very low LDL levels are achievable with alirocumab, and about 40% of patients in ODYSSEY OUTCOMES reached LDL below 25 mg/dL at least once during treatment. Safety at these levels appeared acceptable over the 2.8-year follow-up period, though longer-term data beyond 5 years remain limited. [3]

The Clinical Evidence Base: ODYSSEY OUTCOMES and Beyond

ODYSSEY OUTCOMES remains the defining cardiovascular outcomes trial for alirocumab. Published in the New England Journal of Medicine in November 2018, the trial enrolled 18,924 patients with acute coronary syndrome within the prior 1 to 12 months, all on high-intensity or maximally tolerated statin therapy. [3] Mean baseline LDL was 87 mg/dL. The drug reduced LDL by a mean of 54.7% at 4 months. The primary endpoint reduction of 15% (HR 0.85) translated into an absolute risk reduction of 1.6 percentage points over 2.8 years, with the number-needed-to-treat dropping to 16 in the highest-risk subgroup. [3]

A pre-specified mortality analysis found that alirocumab reduced all-cause mortality by 15% (HR 0.85 to 95% CI 0.73 to 0.98) in the full trial population, a finding that has been cited in ACC/AHA guideline updates as supporting the drug's use in very-high-risk patients. [4]

The ODYSSEY FH I and FH II trials, which specifically enrolled HeFH patients, showed mean LDL reductions of 48.8% and 48.7% respectively at 24 weeks versus placebo, with both trials reaching P<0.0001. [12] These results underpinned the FDA approval for the HeFH indication and inform Delaware Medicaid's PA criteria for that population.

Alirocumab has also been studied in statin-intolerant patients. ODYSSEY ALTERNATIVE compared alirocumab to ezetimibe in patients with muscle-related statin intolerance and found that alirocumab reduced LDL by 45% versus 15% for ezetimibe at 24 weeks, with muscle-related adverse events occurring in 32.5% of the alirocumab arm versus 46.0% in the atorvastatin rechallenge arm embedded in the trial. [13] This positions alirocumab as an option for Delaware patients who cannot tolerate any statin at full dose.

Delaware-Specific Regulatory and Pharmacy Notes

Delaware's Board of Pharmacy licenses 503A compounding pharmacies under Title 24, Chapter 25 of the Delaware Code, consistent with federal USP 797 sterile compounding standards. A compounding pharmacy that fills a patient-specific alirocumab prescription must comply with sterility testing, beyond-use dating, and labeling requirements under state and federal law. [8]

Delaware does not have a state-level PCSK9 inhibitor mandate requiring commercial insurers to cover alirocumab without PA. However, Delaware's insurance code requires insurers to complete PA determinations within 72 hours for urgent requests and 5 business days for non-urgent requests under 18 Del. C. § 3342A. Failure to meet those timelines allows the prescriber to appeal directly to the Delaware Department of Insurance. [14]

The Delaware Division of Medicaid and Medical Assistance (DMMA) publishes its preferred drug list quarterly. Prescribers can confirm current PA criteria and preferred alternatives at the DMMA pharmacy portal. As of the most recent published PDL update, alirocumab is listed as covered with PA and evolocumab (Repatha) is listed as an alternative PCSK9 inhibitor also covered with PA under the same criteria. [6]

Comparing Alirocumab to Evolocumab in Delaware

Delaware patients and prescribers sometimes ask whether alirocumab or evolocumab is better covered or cheaper in the state. Both drugs are FDA-approved PCSK9 inhibitors with similar mechanisms and efficacy. [1] The FOURIER trial for evolocumab (N=27,564) showed a 15% relative reduction in the primary endpoint (HR 0.85), nearly identical to ODYSSEY OUTCOMES for alirocumab. [15]

From a Delaware Medicaid standpoint, both are covered with PA and subject to the same clinical criteria. Commercial plan formularies vary: some carriers list alirocumab as preferred and evolocumab as non-preferred, and others do the reverse. The practical approach is to check your specific plan's current formulary before the prescriber submits the PA, then select the preferred agent.

List prices are similar between the two products. The manufacturer savings card programs are structurally similar as well. If formulary placement is equal between the two drugs on your plan, clinical considerations (such as the monthly 300 mg dosing option for alirocumab, which evolocumab does not offer) may tip the choice.